Delving into the Latest Updates on Shanghai Xitaili Biomedical Technology Co., Ltd. with Synapse

Overview

Tags

Endocrinology and Metabolic Disease

Fc fusion protein

Recombinant polypeptide

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Endocrinology and Metabolic Disease	1

Top 5 Drug Type	Count

Fc fusion protein	1
Recombinant polypeptide	1

Top 5 Target	Count

GCGR x GLP-1R x Mas receptor	1

This is a multicenter, randomized, double-blind, placebo-controlled Phase I study to evaluate safety, PK and PD of single ascending dose (SAD) and multiple ascending dose (MAD) of XTL6001 injection in healthy and obese adult subjects.
SAD study: Includes 5 dose cohorts, with 40 subjects planned for enrollment. MAD study Includes 2 dose cohorts, with 30 subjects planned for enrollment.

Start Date13 Jun 2025

Sponsor / Collaborator

Shanghai Xitaili Biomedical Technology Co., Ltd.

100 Clinical Results associated with Shanghai Xitaili Biomedical Technology Co., Ltd.

Login to view more data

0 Patents (Medical) associated with Shanghai Xitaili Biomedical Technology Co., Ltd.

Login to view more data

100 Deals associated with Shanghai Xitaili Biomedical Technology Co., Ltd.

Login to view more data

100 Translational Medicine associated with Shanghai Xitaili Biomedical Technology Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 27 Jul 2026

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 1

1

Login to view more data